Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark…
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for…
NCQA HEDIS-certified CareProminence 360Measures™ technology enhances population health management for health plans and pharmacy benefit managers TAMPA, Fla., Sept. 26,…
Industry experts gather to discuss strategies and share insights for advancing value-based care success. DALLAS, Sept. 26, 2024 /PRNewswire/ --…
PHILADELPHIA, Sept. 26, 2024 /PRNewswire/ -- Alivia Analytics, a leading AI-powered healthcare data analytics and technology company, announced the appointment…
Robust new feature available exclusively through Integrity's industry-leading MedicareCENTER empowers agents to serve consumers more efficiently and effectively than ever…
New Business Line Formed to Address Mounting Needs of Medicare Advantage, Medicaid, Home Health, and Senior Living Organizations WASHINGTON, Sept.…
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared…
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old…
BETHESDA, Md., Sept. 19, 2024 /PRNewswire/ -- Fifty-six million children and youth spend more than a quarter of their day…